Compare PCRX & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | KODK |
|---|---|---|
| Founded | 2006 | 1880 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 982.9M |
| IPO Year | 2010 | 1994 |
| Metric | PCRX | KODK |
|---|---|---|
| Price | $24.00 | $9.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | 430.8K | ★ 708.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | $541,533,000.00 | ★ $4,114,000,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $129.32 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $5.78 |
| 52 Week High | $27.66 | $14.87 |
| Indicator | PCRX | KODK |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 60.25 |
| Support Level | $21.97 | $8.87 |
| Resistance Level | $27.05 | $10.26 |
| Average True Range (ATR) | 0.74 | 0.27 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 22.70 | 93.24 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.